Form 4: DBV Technologies CFO Acquires Shares and Options in Recent Transaction

DBV Technologies' Chief Financial Officer, Virginie Boucinha, acquired 19,000 ordinary shares and 113,000 stock options on November 21, 2024.

Summary

• Virginie Boucinha, the Chief Financial Officer of DBV Technologies S.A., has reported a transaction involving the company's securities.
• On November 21, 2024, Ms. Boucinha acquired 19,000 ordinary shares through a restricted stock unit (RSU) award.
• These RSUs will vest in four equal annual installments starting November 21, 2025, contingent on her continued service.
• Additionally, she acquired 113,000 employee stock options with an exercise price of $0.75 per share.
• These options also vest in four equal annual installments beginning November 21, 2025, subject to her continued employment.
• The exercise price of the options is based on a Euro to USD conversion rate of $1.0546 per Euro as of November 21, 2024.
• Following these transactions, Ms. Boucinha now beneficially owns 38,000 ordinary shares and 113,000 stock options.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative sentiment.

Positives

• The acquisition of shares and options by the CFO demonstrates her commitment to the company's future.
• The vesting schedule of the shares and options aligns the CFO's interests with the long-term performance of the company.

Risks

• The vesting of the shares and options is contingent on the CFO's continued employment, which introduces a risk of forfeiture if she leaves the company before full vesting.

Future Outlook

The vesting of the shares and options is contingent on the CFO's continued service, suggesting a long-term commitment to the company.

Industry Context

This type of transaction is common for executive compensation, aligning management's interests with those of shareholders. It is a standard practice in publicly traded companies to grant stock options and restricted stock units to key personnel.

Comparison to Industry Standards

• The vesting schedule of four equal annual installments is a common practice for stock options and restricted stock units in the biotechnology industry.
• The exercise price of $0.75 per share for the stock options is typical for early-stage biotech companies, often set at or near the current market price at the time of grant.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• The transaction aligns the CFO's interests with those of shareholders, potentially leading to increased focus on long-term value creation.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

DBV Technologies, Virginie Boucinha, stock options, restricted stock units, insider trading, executive compensation, share acquisition